Health
Targeted therapies developed to reduce lung fibrosis – Medical Xpress
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
People with idiopathic pulmonary fibrosis (IPF) have a life expectancy of less than five years. Fibrotic diseases cause organ failure that lead to about 45% of all deaths in the United States. Existing therapies do little to slow progression.
Now, Philip S. Low, the Purdue Ralph C. Corley Distinguished Professor of Chemistry and Presidential Scholar…
-
Business22 hours ago1 Australian stock you’ll probably kick yourself for not owning a decade from now
-
General22 hours agoTrolls stole Dr Juliet Turner’s joy and in doing so took their own
-
General19 hours agoProtecting victims of explicit AI content online
-
Business21 hours agoIs this the best ASX ETF to diversify your portfolio with?